ShanghaiApril 28, 2026 /PRNewswire/ — On April 28, 2026, the second phase of Fibman Biotechnology’s Changchun Jingyue factory officially broke ground, marking a key step forward in the company’s full-chain layout of active collagen and its upgrade to intelligent manufacturing.
Group photo at the groundbreaking ceremony for the second phase of Fibman Biotechnology’s Changchun Jingyue factory
The second phase of Fibman Biotechnology’s Jingyue factory, which has now commenced construction, is planned to invest 300 million yuan. Combined with the already operational first phase of the Jingyue factory, the total investment has approached 1 billion yuan. Upon completion, the total building area of the Jingyue factory site will be nearly 50,000 square meters. The project is centered on high-standard intelligent design, establishing a digital production system, automated production lines, and a full-process quality control platform. It aims to create an active collagen intelligent production and R&D platform integrating research and development, pilot testing, and large-scale production, comprehensively enhancing production efficiency and product quality, and setting a new benchmark for intelligent manufacturing in the industry.
As an evolution and upgrade of the first phase’s full industrial chain, the second phase factory will delve deeper into novel formulations while comprehensively laying out tracks for collagen peptide raw materials, medical dressings, and high-end biomaterials. The project will also introduce top-tier industry talent, creating a biotechnology hub that integrates technological breakthroughs, transformation of scientific research achievements, and intelligent manufacturing. This will enable the deep application of active collagen across multiple fields and scenarios in medical aesthetics, healthcare, and general wellness.
As a leading enterprise focused on the R&D, production, and application of active collagen, Fibman Biotechnology has built an industry-leading full-chain R&D and production platform from raw materials to end products. This is supported by its EU-standard self-built medical-grade cattle farm and its ISO 13485-certified collagen intelligent factory. The company holds over 50 core patented technologies, including organ transplant-grade active collagen extraction and controllable self-assembly of collagen fibers. Through deep collaboration with renowned domestic research institutions and universities, it is an innovative biotechnology enterprise that has achieved the first fully independent and controllable active collagen full industrial chain in China.
Speech by Mr. Chen Xinwei, Managing Director of Fibman Biotechnology
Chen Xinwei, Managing Director of Fibman Biotechnology, stated: “We will pursue intelligent, high-end, and international development, building an industrial closed loop of ‘basic research — laboratory incubation — large-scale intelligent manufacturing,’ and deepening the integration of industry, academia, and research. In the future, Fibman Biotechnology will continue to build a ‘medical aesthetics + healthcare + wellness’ three-in-one ecosystem centered on active collagen technology, driving industrial upgrading with core technology and leading China’s active collagen industry toward the high end of the global value chain.”
The company has been recognized as a national high-tech enterprise, a national intellectual property advantage enterprise, a Jilin Province specialized and new enterprise, a Jilin Province intelligent factory, and a Jilin Province green factory. The implementation of this project further perfects Fibman Biotechnology’s complete layout from R&D to large-scale intelligent production. Moving forward, Fibman Biotechnology will continue to increase innovation investment, strengthen technological barriers and industrial advantages, and inject stronger momentum into the development of China’s high-end biomaterials industry and national health initiatives.